Condition: Multiple Myeloma · Sponsor: AbbVie
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional g…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - Main /ID# 261434 | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic Hospital - Phoenix /ID# 263326 | Phoenix, Arizona, United States | Recruiting |
| Alta Bates Summit Medical Center for Research /ID# 261438 | Berkeley, California, United States | Completed |
| Providence - St. Jude Medical Center /ID# 262031 | Fullerton, California, United States | Recruiting |
| VA Loma Linda Healthcare System /ID# 261015 | Loma Linda, California, United States | Recruiting |
| Cedars-Sinai Medical Center /ID# 261008 | Los Angeles, California, United States | Recruiting |
| Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 | Lone Tree, Colorado, United States | Recruiting |
| Mayo Clinic Hospital Jacksonville /ID# 263324 | Jacksonville, Florida, United States | Recruiting |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 | Jacksonville, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University /ID# 262525 | Atlanta, Georgia, United States | Recruiting |
| University of Illinois Hospital and Health Sciences System /ID# 246349 | Chicago, Illinois, United States | Recruiting |
| Rush University Medical Center /ID# 265690 | Chicago, Illinois, United States | Completed |
+ 154 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06158841